Lorus Therapeutics 2012 Annual and Special Meeting of

Lorus Therapeutics 2012 Annual and Special Meeting of Shareholders
Announcement 
TORONTO, ONTARIO -- (Marketwire) -- 11/28/12 -- Lorus Therapeutics
Inc. (TSX:LOR) ("Lorus"), a biopharmaceutical company specializing in
the discovery, research and development of pharmaceutical products
and technologies for the management of cancer, announced that the
Lorus Therapeutics 2012 Annual and Special Meeting of Shareholders
will be held on November 29, 2012 at 10:00am EST.  


 
Location: The Offices of McCarthy Tetrault LLP                              
          Toronto Dominion Bank Tower                                       
          66 Wellington Street West, Suite 5300                             
          Clarkson Room                                                     
          Toronto, Ontario                                                  

 
To listen to this event, please enter:
https://webcasts.welcome2theshow.com/lorusagm2012 on the web browser. 
About Lorus  
Lorus is a biopharmaceutical company focused on the discovery,
research and development of novel therapeutics in cancer. Lorus' goal
is to capitalize on its research, preclinical, clinical and
regulatory expertise by developing new drug candidates that can be
used, either alone, or in combination with other drugs, to
successfully manage cancer. The Company also has expertise in
antimicrobial drug discovery. Lorus Therapeutics Inc. is listed on
the Toronto Stock Exchange under the symbol LOR. 
Forward-Looking Statements  
This press release may contain forward-looking statements within the
meaning of Canadian and U.S. securities laws. Such statements
include, but are not limited to, statements relating to: our ability
to fund future research, our research program plans, our plans to
conduct clinical trials, the successful and timely completion of
clinical studies and the regulatory approval process, our ability to
continue as a going concern, our ability to obtain partners to assist
in the further development of our product candidates, the
establishment of corporate alliances, the Company's plans,
objectives, expectations and intentions and other statements
including words such as "continue", "believe", "plan", "expect",
"intend", "will", "should", "may", and other similar expressions.
Such statem
ents reflect our current views with respect to future
events and are subject to risks and uncertainties and are necessarily
based upon a number of estimates and assumptions that, while
considered reasonable by us are inherently subject to significant
business, economic, competitive, political and social uncertainties
and contingencies. Many factors could cause our actual results,
performance or achievements to be materially different from any
future results, performance, or achievements that may be expressed or
implied by such forward-looking statements, including, among others:
our ability to continue as a going concern, our ability to obtain the
capital required for research and operations, the inherent risks in
early stage drug development including demonstrating efficacy,
development time/cost and the regulatory approval process; the
progress of our clinical trials; our ability to find and enter into
agreements with potential partners; our ability to attract and retain
key personnel; changing market conditions; and other risks detailed
from time-to-time in our ongoing quarterly filings, annual
information forms, annual reports and annual filings with Canadian
securities regulators and the United States Securities and Exchange
Commission.  
Should one or more of these risks or uncertainties materialize, or
should the assumptions set out in the section entitled "Risk Factors"
in our Annual Information Form underlying those forward-looking
statements prove incorrect, actual results may vary materially from
those described herein. These forward-looking statements are made as
of the date of this press release and we do not intend, and do not
assume any obligation, to update these forward-looking statements,
except as required by law. We cannot assure you that such statements
will prove to be accurate as actual results and future events could
differ materially from those anticipated in such statements.
Investors are cautioned that forward-looking statements are not
guarantees of future performance and accordingly investors are
cautioned not to put undue reliance on forward-looking statements due
to the inherent uncertainty therein.  
Lorus Therapeutics Inc.'s recent press releases are available through
the Company's website at www.lorusthera.com. For Lorus' regulatory
filings on SEDAR, please go to www.sedar.com.
Contacts:
Lorus Therapeutics Inc.
Grace Tse
416-798-1200 ext. 380
ir@lorusthera.com
www.lorusthera.com